Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) EBT (2016 - 2025)

Guided Therapeutics' EBT history spans 16 years, with the latest figure at -$1.2 million for Q4 2025.

  • On a quarterly basis, EBT fell 86.81% to -$1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.2 million, a 32.31% decrease, with the full-year FY2025 number at -$3.2 million, down 32.23% from a year prior.
  • EBT hit -$1.2 million in Q4 2025 for Guided Therapeutics, down from -$742000.0 in the prior quarter.
  • Over the last five years, EBT for GTHP hit a ceiling of $68000.0 in Q3 2021 and a floor of -$1.8 million in Q4 2022.
  • Historically, EBT has averaged -$768650.0 across 5 years, with a median of -$693000.0 in 2023.
  • Biggest five-year swings in EBT: skyrocketed 84.68% in 2021 and later tumbled 1720.59% in 2022.
  • Tracing GTHP's EBT over 5 years: stood at -$444000.0 in 2021, then crashed by 306.98% to -$1.8 million in 2022, then soared by 78.64% to -$386000.0 in 2023, then plummeted by 68.91% to -$652000.0 in 2024, then crashed by 86.81% to -$1.2 million in 2025.
  • Business Quant data shows EBT for GTHP at -$1.2 million in Q4 2025, -$742000.0 in Q3 2025, and -$811000.0 in Q2 2025.